Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets for nonalcoholic fatty liver disease (NAFLD).

Last week, the scientists published a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics. Sequence variants that associate with NAFLD were identified, including rare, protective loss-of-function variants that point to potential drug targets. Plasma proteomic analyses provided further insight into the pathogenesis of  NAFLD

A path to the development of non-invasive tools

A large genome-wide association study of NAFL, liver cirrhosis and HCC was conducted and the findings integrated with expression and proteomic data. For NAFL, 9,491 clinical cases from Iceland, the UK, USA and Finland were utilized in addition to proton density fat fraction (PDFF) extracted from 36,116 liver MRIs. Among the sequence variants discovered, in the Icelandic population, were rare, protective, predicted loss-of-function variants in MTARC1 and GPAM suggesting that inhibiting MTARC1 or GPAM could be therapeutic for NAFL or NASH.

Levels of thousands of proteins measured in plasma were analyzed, identifying potential biomarkers of disease, disease progression, or target engagement, and models that can discriminate between a NAFLD and cirrhosis were constructed using the proteomics data. The results, therefore, provide a path to the development of non-invasive tools to evaluate and diagnose NAFLD.

One of the largest ones conducted on the genetic basis of NAFLD

Additionally, the pleiotropic effects of the identified variants were explored by looking at associations with 52 other phenotypes and traits. BMI is one of the most common risk factors of NAFLD and longitudinal PDFF measures suggested that carriers of p.Ile148Met, the well-know NAFLD risk variant, in PNPLA3 are more susceptible to change in BMI than non-carriers.

To date, this study is one of the largest ones conducted on the genetic basis of NAFLD and the results will hopefully contribute to the development of diagnostic tools and therapies that can help patients suffering from NAFLD.

Photo: deCODE genetics lab